[Congressional Record Volume 166, Number 110 (Monday, June 15, 2020)]
[Senate]
[Page S2975]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                         SUBMITTED RESOLUTIONS

                                 ______
                                 

  SENATE RESOLUTION 617--DESIGNATING JULY 22, 2020, AS ``GLIOBLASTOMA 
                            AWARENESS DAY''

  Mr. GRAHAM (for himself, Mr. Markey, Ms. McSally, Ms. Sinema, and Ms. 
Warren) submitted the following resolution; which was referred to the 
Committee on the Judiciary:

                              S. Res. 617

       Whereas more than 13,000 new cases of glioblastoma will be 
     diagnosed in the United States in 2020;
       Whereas glioblastoma is--
       (1) the most common malignant (cancerous) brain tumor, 
     accounting for 48 percent of all primary malignant brain 
     tumors; and
       (2) the most aggressive, complex, difficult to treat, and 
     deadly type of brain tumor;
       Whereas it is estimated that more than 10,000 individuals 
     in the United States will succumb to glioblastoma every year;
       Whereas the 5-year survival rate for glioblastoma patients 
     is only 6.8 percent, and the average length of survival for 
     glioblastoma patients is estimated to be only 12 to 18 
     months;
       Whereas glioblastoma is described as a disease that affects 
     the ``essence of self'', as the treatment and removal of 
     glioblastoma presents significant challenges due to the 
     uniquely complex and fragile nature of the brain, the primary 
     organ in the human body that controls not only cognitive 
     ability, but also the actions of every organ and limb;
       Whereas, relative to other types of cancers, brain cancer 
     has--
       (1) the highest per-patient initial cost of care, with an 
     annualized mean net cost of care approaching $150,000; and
       (2) the highest annualized mean net costs for last-year-of-
     life care, with a cost of between $135,000 and $210,000 per 
     patient, depending on the age and gender of a patient;
       Whereas, although research advances may fuel the 
     development of new treatments for glioblastoma, challenging 
     obstacles to accelerating progress toward new treatments for 
     glioblastoma remain, and there are no screening or early 
     detection methods;
       Whereas, although glioblastoma was first described in 
     medical and scientific literature in the 1920s, and despite 
     its devastating prognosis, only 4 drugs and 1 medical device 
     have been approved by the Food and Drug Administration to 
     treat glioblastoma since the 1920s, and the mortality rates 
     associated with glioblastoma have changed little during the 
     past 30 years; and
       Whereas there is a need for greater public awareness of 
     glioblastoma, including awareness of both--
       (1) the urgent unmet medical needs of glioblastoma 
     patients; and
       (2) the opportunities for research and treatment advances 
     for glioblastoma: Now, therefore, be it
       Resolved, That the Senate--
       (1) designates July 22, 2020, as ``Glioblastoma Awareness 
     Day'';
       (2) encourages increased public awareness of glioblastoma;
       (3) honors the individuals who have lost their lives to 
     glioblastoma, a devastating disease, or are currently living 
     with it;
       (4) supports efforts to develop better treatments for 
     glioblastoma that will improve the long-term prognosis of 
     individuals diagnosed with glioblastoma;
       (5) expresses its support for the individuals who are 
     battling brain tumors, as well as the families, friends, and 
     caregivers of those individuals; and
       (6) urges a collaborative approach to brain tumor research, 
     which is a promising means of advancing the understanding and 
     treatment of glioblastoma.

                          ____________________